Verastem Inc. (VSTM)
Verastem Inc. (VSTM) Stock Price, Analysis & Data
| Bid | 4.98 |
| Market Cap | 595.91M |
| Revenue (ttm) | 87.53M |
| Net Income (ttm) | -202.7M |
| Beta | 0.29 |
| EPS (ttm) | -2.44 |
| PE Ratio (ttm) | n/a |
| Forward PE | -8.77 |
| P/B (ttm) | 7.07 |
| P/S (ttm) | 6.81 |
| Earnings Date | Nov 3, 2026 |
| Ask | 8.69 |
| Volume | 1,280,177 |
| Avg. Volume (20D) | 2,528,622 |
| Open | 6.66 |
| Previous Close | 6.67 |
| Day's Range | 6.45 - 6.66 |
| 52-Week Range | 3.43 - 11.25 |
| Analyst | Strong Buy |
| Price Target | 15 (127.96%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About VSTM
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway that is commonly activated in v...
Financial Performance
In 2025, Verastem's revenue was 30.91M, an increase of 209.14% compared to the previous year's 10M. Earnings were -209.47M, an increase of 60.35%.
Financial StatementsAnalyst Forecast
According to 8 analyst ratings, the average rating for VSTM stock is "Strong Buy". The 12-month stock price forecast is 15, which is upside of 127.96% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
